←
Michael Yan, MD MPH273 posts
Michael Yan, MD MPH avatar

Michael Yan, MD MPH

@MichaelYanMD

🇨🇦 |Radiation Oncologist @RadMedPM @PMcancercentre @UofTdro | Alumnus @Sunnybrook @QueensOncology @JohnsHopkinsSPH @SchulichMedDent | Views = mine

◷ Joined January 2012▧ 12 Photos and videos
Dr. Nina Niu Sanford avatar
⟳ Michael Yan, MD MPH retweeted
Dr. Nina Niu Sanford@NiuSanford·Oct 3

Enjoyed this session & learned a lot! Both TARE & SBRT can deliver ablative RT in HCC. Key q is which approach is best suited for a given pt/tumor. Sharing some of my slides below re: decision-making b/w the 2 modalities. TY to @GIcancerDoc & @EileenMOReilly for the invite.

Post attachmentPost attachmentPost attachmentPost attachment

This should be a great meeting. Look forward to debating on SBRT vs. Y90 for HCC 🙂 Join us in Ft. Lauderdale or virtually 10/2-3!

Post attachment
Lauren Henke, MD, MSCI avatar
⟳ Michael Yan, MD MPH retweeted
Lauren Henke, MD, MSCI@lauren_henke·Sep 26

⚡️Thrilled and proud are words that just do not do justice to getting to work with our @RadOncUH team & collaborators to help bring #Accela to (pre-)clinical life, first in the world on the SPEED clinical trial this August, thanks to tireless efforts by @APrice_BeamOn @Betyguevarasoto @DrSpratticus @angela_jia_ @KashaniRojano and countless others with our partners @SiemensHealth and academic partners at @WashUMedRadOnc @MayoRadOnc @MSK_RadOnc @MGBResearchNews @RadOncUSZ and @MAASTROclinic

Post attachmentPost attachmentPost attachment

#ASTRO26 @lauren_henke from @RadOncUH showing the data from the very first patients in the world on the SPEED trial using Varians new Accela unit. @ASTRO_org @ASCO @NRGonc @NehaVapiwala @HimanshuNagarMD @AmarUKishan @APrice_BeamOn @angela_jia_ @KashaniRojano @PranshuMohindra @Soum_Roy_RadOnc @HaleyPerlow @DrewMoghanaki @MayoClinic @MSKCancerCenter

0:36
The Lancet avatar
⟳ Michael Yan, MD MPH retweeted
The Lancet@TheLancet·Sep 25

Radiotherapy after surgery halves risk of recurrence in a type of brain tumour that can often grow back, trial shows. Find out more in The Lancet: spkl.io/60137TUFS #EANO2026

Post attachment
Erman Akkus avatar
⟳ Michael Yan, MD MPH retweeted
Erman Akkus@Erman_Akkus·Sep 25

Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial thelancet.com/journals/lanep…

Dr. Nina Niu Sanford avatar
⟳ Michael Yan, MD MPH retweeted
Dr. Nina Niu Sanford@NiuSanford·Jul 9

Really useful app for estimating OAR cumulative dose & dose reserve for re-irradiation planning by @jryckman3! We are going to record a video going through some case examples. Let us know if any specific qs. radonc.org/reirradiation

Post attachment

ReRT planning is hard. So we built a free EQD2-based D0.1cc calculator to help estimate remaining OAR reserve across prior RT courses, with both no-forgiveness and time-forgiveness options. Decision support only. Use judgment. Verify independently. #RadOnc #OncTwitter

Michael Chuong avatar
⟳ Michael Yan, MD MPH retweeted
Michael Chuong@MikeChuongMD·May 6

Ablative RT often causes tissue changes within a few mm outside of the target lesion Can give the appearance of tumor "growth" when this often is pseudoprogression CT/MRI reports often do not reflect this possibility Larger size does not always mean local failure!!

Piet Ost avatar
⟳ Michael Yan, MD MPH retweeted
Piet Ost@piet_ost·Apr 28

1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation. On behalf of the EORTC–ESTRO OligoCare consortium.

Post attachment
Bishal Gyawali, MD, PhD, FASCO avatar
⟳ Michael Yan, MD MPH retweeted
Bishal Gyawali, MD, PhD, FASCO@oncology_bg·Apr 23

Wow. Thank you everyone for such an amazing response to this article. 60K views in 24 hrs for an academic article in the current era of X is truly encouraging. Speaks to the “unmet need” of educational resources for critical appraisal. ascopubs.org/doi/10.1200/OP-…

A MUST-READ! This is probably one of my most important papers where I try to teach how to fish rather than offer fish. How I Read a Clinical Trial Report? BG’s primer for Busy Clinicians. Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful. ascopubs.org/doi/10.1200/OP-…

Post attachment
Joshua D. Palmer, MD avatar
⟳ Michael Yan, MD MPH retweeted
Joshua D. Palmer, MD@joshuapalmermd·Apr 8

Check out our amazing meta analysis FIRE-STORM, showing PFS significantly better with DE-RT over 66 Gy in 33 for high grade meningioma. We hope this will help as we prepare to show for over 70 Gy improves control in future trial!! redjournal.org/article/S0360…

Mark Yarchoan avatar
⟳ Michael Yan, MD MPH retweeted
Mark Yarchoan@MarkYarchoan·Feb 14

Barcelona HCC classification may not reflect current treatment practices in US The new BEACON-HCC Classification was introduced for comment today @HCCLIVEConf - pls weigh in! Pilot real-world cases: Expert concordance 100% with BEACON-HCC vs 58.6% with 2022 #BCLC

Post attachment
Aisling Barry avatar
⟳ Michael Yan, MD MPH retweeted
Aisling Barry@aislingbarryro·Jan 15

#HRQOL #oligoprog #SBRT 🔥RADIANT - phII oligoprog GI, GU, breast 🔵 secondary outcome - HRQOL ⬇️ mean global health SS but not clinically significant at 6m 🔵disease progression predictor of worse HRQOL on MVA 🔵if no prog HRQOL was stable or improved in 83% 1/

Jane Jomy avatar
⟳ Michael Yan, MD MPH retweeted
Jane Jomy@JaneJomy·Jan 16

𖠣 New in @TheJNS Spine: Does timing matter? Analysis led by @MichaelYanMD @UHN found improved locoregional cancer control among patients who receive radiotherapy before vertebral augmentation for spine metastases: tinyurl.com/3k9ckx32 @UofTDRO @UofTNeuroSurge @UofTMedIm